We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Assessment shows therapeutic candidate romidepsin demonstrates dose responses in osteosarcoma, indicating its potential in treatment strategies.
Dose responses and ED50s from secondary screen
No takes yet. Share an insight, caveat, or question.
Seiden et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: